Reversing a genetic mutation to restore your smile
(University of Utah Health) Rena D'Souza, D.D.S., Ph.D., Professor of Dentistry at the University of Utah Health received a grant from the National Institutes of Health to build on her past research to characterize the genetics that prevent tooth formation and develop therapies to reverse this process.
Authors: Moskowitz CH PMID: 29036042 [PubMed - in process]
Authors: PMID: 29036041 [PubMed - in process]
Authors: Furman RR PMID: 29036040 [PubMed - in process]
Authors: Johnson MS PMID: 29036039 [PubMed - in process]
Authors: Johnson MS PMID: 29036038 [PubMed - in process]
Authors: Zhu AX PMID: 29036037 [PubMed - in process]
Authors: El-Serag HB PMID: 29036036 [PubMed - in process]
Authors: El-Serag HB, Zhu AX, Johnson MS Abstract The treatment approach for hepatocellular carcinoma (HCC) depends on the stage and extent of disease, the severity of the underlying liver disease, and the overall performance status of the patient. Treatment consists of 4 main strategies: surgery (eg, resection and liver transplant), locoregional procedures (eg, ablation and transarterial embolization), systemic therapies, and best supportive care. For patients with early-stage tumors, surgical treatment or ablation can be curative. Patients with intermediate-stage disease can be candidates for embolization, admini...
Authors: Mazighi M Abstract The therapeutic management of acute ischemic stroke has changed tremendously over the past few years. Mechanical thrombectomy in addition to intravenous tissue plasminogen activator (t-PA) is currently the standard of care for patients experiencing acute ischemic stroke as a consequence of large vessel occlusion of the anterior circulation. Yet, despite strong evidence supporting such a therapeutic approach, several issues remain a source of debate, such as the need for intravenous t-PA, the optimal target for blood pressure levels and the opportunity for additional antithrombotic therap...
Authors: Detante O, Rome C, Papassin J Abstract Regenerative cell therapy is a promising therapeutic strategy in neurology, most notably to improve stroke recovery. Although tolerability and feasibility have apparently been validated, many questions remain as to what is the best type of cells to use, the best route and the post-stroke delay for administration. Two main strategies have currently emerged: intravenous injection of mesenchymal stem cells with systemic trophic support; and intracerebral grafting of neural stem cells with brain repair effects at the lesion site. Multicenter clinical trials have just begu...